Personalized medicine begins with you
Who we are
Aspen is dedicated to developing and delivering iPSC- derived autologous cell replacement therapies for patients with high unmet medical need, beginning with Parkinson’s disease (PD).
We aim to transform the lives of people living with PD with our personalized regenerative therapies that offer real hope where none existed before.
What we do
Addressing Patient Need
Parkinson’s remains a disease of high unmet need, affecting millions worldwide, robbing them of movement, cognition, mental health and independence. Current medicines aren’t able to infiltrate the part of the brain implicated in treating or reversing the root cause of disease.
Novel Science
Clinical Results
Aspen uses a person’s own cells to help restore function. These cells are placed right where they’re needed to regenerate the lost dopamine, without the need for immunosuppression, resulting in positive clinical results to date.
Ready to Commercialize
At Aspen’s world-class manufacturing site, our commercial formulation of ANPD001—a first-in-class autologous cell therapy for Parkinson’s disease—is designed for scalable, reproducible manufacturing. Automation, machine learning, and robotics drive efficiency, lower costs, and make personalized cell therapy commercially viable at scale.
Expert Team
Backed by top investors and a seasoned Board of Directors, Aspen’s team includes top scientists, doctors, and people who care deeply about patients. Together, they’re building the future of truly transformative personalized, regenerative medicines.
